DIMERIX LIMITED (DXB)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
DXB - DIMERIX LIMITED
FNArena Sector :
Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0
Index: ALL-ORDS
FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0
| LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
|---|---|---|---|
|
$0.53
16 Oct |
OPEN $0.53 |
HIGH $0.54 |
338,292 LOW $0.53 |
0.005| OTHER COMPANIES IN THE SAME SECTOR | |||
| 1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO . | |||
FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
| Title | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| EPS Basic | xxx | xxx | xxx | xxx | xxx | -2.4 |
| DPS All | xxx | xxx | xxx | xxx | xxx | 0.0 |
| Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 5.6 M |
| Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 2.2 |
| Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | 39.0 M |
| Net Profit Margin | xxx | xxx | xxx | xxx | xxx | -237.20 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
| Title | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | -83.97 % |
| Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | -83.78 % |
| Return on Assets | xxx | xxx | xxx | xxx | xxx | -21.50 % |
| Return on Equity | xxx | xxx | xxx | xxx | xxx | -83.97 % |
| Return on Total Capital | xxx | xxx | xxx | xxx | xxx | -201.24 % |
| Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | 39.0 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
| Title | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 0 M |
| Long Term Debt | xxx | xxx | xxx | xxx | xxx | 0 M |
| Total Debt | xxx | xxx | xxx | xxx | xxx | 0 M |
| Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | - |
| Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 68 M |
| Price To Book Value | xxx | xxx | xxx | xxx | xxx | 25.73 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
| Title | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Capex | xxx | xxx | xxx | xxx | xxx | 0.0 M |
| Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 0.38 % |
| Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | - |
| Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 37 M |
| Research & Development | xxx | xxx | xxx | xxx | xxx | 27 M |
| Investments - Total | xxx | xxx | xxx | xxx | xxx | 0 M |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
EXTRA COVERAGE
Display All Commentary
No. Of Recommendations
Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.
DXB STOCK CHART
FNArena News on DXB
Latest Pharmaceuticals & Biotech/Lifesciences News
| 1 |
Is CSL Starting Its Price Recovery?Sep 30 2025 - Technicals |
| 2 |
Undervalued ASX Gems In Precision MedicineSep 23 2025 - Small Caps |
| 3 |
Earnings Result Leaves CSL BloodiedAug 21 2025 - Australia |
| 4 |
Renewed Momentum For CSL SharesJul 22 2025 - Technicals |
| 5 |
Treasure Chest: CSL Not A One-Trick PonyJul 14 2025 - Treasure Chest |
| 6 |
The Enigma Surrounding ClinuvelJul 03 2025 - Small Caps |
| 7 |
Rudi’s View: CSL & NextDCMay 08 2025 - Rudi's View |
| 8 |
Behring Margin Outlook Still Main Game For CSLFeb 13 2025 - Australia |
| 9 |
Dr Boreham’s Crucible: Arovella TherapeuticsAug 29 2024 - Small Caps |
| 10 |
ResMed’s Margin Upside ExcitesAug 07 2024 - Australia |